We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. (“Global Blood” or the “Company”) (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE).  Under the terms of the merger agreement, the Company’s shareholders will receive $68.50 in cash for each share of Global Blood common stock owned.  The transaction is valued at approximately $5.4 billion.

Weiss Law is investigating whether (i) Global Blood’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $68.50 per-share merger consideration adequately compensates Global Blood’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, at least one analyst set a price target for the Company of $100 per share, $31.50 above the per-share merger consideration.